ARWR’s innovation outlook is trending down based on a current score of 50 out of 99, outperforming sector average. Insiders sentiment is negative. Over the past 4 quarters ARWR beat earnings estimates 1 time. For more analysis and articles visit our website.
Price above the cloud ( bullish )
Above 200MA ( bullish )
Buy $18.00
Take Profit: 21.00 R=2
Stop Loss: $16.50
Not Financial Advice
Thank You
All comments are welcome
ARWR - historically positive ER with ascending price action
afterwards. Closed at previous candlestick resistance at
14.80's, which is also just under significant upper trendline
resistance but resting on 50ma. A break over 15 could see
a push to 100ma. A break over that could see push to 16.50's.
If we get past the 16 mark, we look to fill the gap to even
the...
ARWR gapped up on good news with and has made a very clean wedge on day 2. Volume was very low relative to day 1 but the pattern is very clean here and we are low basing on a daily support. There could be a good opportunity on the open either way this plays out. If we gap under 19 and it fails to recover above 19, I would look to short. If we gap above would also...
The last four days have been nice and tight, holding the gains made on the breakout 03/05. The decreasing volume coinciding with fact that the overall daily ranges of the last 4 days have been decreasing add another layer of bullishness. I have noticed the high of the last four days has been decreasing and I think this can be used to determine if the stock is...
This one is moving just as one could hope for, but flags can be pretty unsettling when they're forming. ARWR retreated about 21% over three weeks before resuming its upward trend. It's hard to say whether it takes good nerves to hold tough, or desperate optimism!
Stock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies.
Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL
Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's...
NASDAQ:ARWR just reached a previous top and has gone down 3 days in a row. Selling pressure is increasing. It just broke a trend line that was consistent for 21 days. Price Oscillator and RSI both broke significant trendlines on 3/6. MACD just had a negative crossover indicating a sell signal. CMF is downtrending and the Parabolic SAR is close to negatively...
NASDAQ:ARWR The next couple of days will determine a short term potentially sharp uptrend or downtrend. RSI just crossed through a trendline and if price confirms and breaks trend, it could see a sharp downtrend. My MACD sell trigger is converging negatively which means a sell signal could come soon. CMF has been in a small price range the past 3 days that could...
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
ARWR
